Sign Out
Trulicity is indicated in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus to improve glycaemic control as: Monotherapy: When diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.
Add-on therapy: In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see Pharmacology: Pharmacodynamics under Actions for data with respect to different combinations).
Trulicity is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke): in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors without established cardiovascular disease; in adults with type 2 diabetes mellitus with established cardiovascular disease (see Pharmacology: Pharmacodynamics under Actions).
Continue with Google